william tremaine cv

TremaineCV.htm[4/8/2015 8:48:29 AM]

Curriculum VitaeWilliam J. Tremaine, MD

1. Personal Information

2. Present Academic Rank and PositionConsultant - Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota

07/1981 - Present

Professor of Medicine - Mayo Clinic College of Medicine 07/2001 - Present

3. EducationVanderbilt University - BA 1972

University of Mississippi, Jackson - MD 1976

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Resident 1976 - 1979

Mayo Graduate School of Medicine, Mayo Clinic College of Medicine - Fellow, Gastroenterology

1979 - 1981

4. CertificationsBoard Certifications

American Board of Internal Medicine (ABIM)

Internal Medicine 1979 - Present

Internal Medicine 1981 - Present

National Board of Medical Examiners (NBME)

Diplomate 1977 - Present

5. LicensureMinnesota 23670 (Medical) 01/1977 - Present

6. Honors/AwardsMerck Award - University of Mississippi Medical Center School of Medicine 01/1976J. Arnold Bargen Award for Outstanding Achievement as a Subspecialty Trainee in Gastroenterology - Mayo Graduate School of Medicine, Mayo Clinic College of Medicine

01/1981

Certificate of Appreciation: Drug Evauations - American Medical Association 01/1991Henry S. Plummer Distinguished Physician Award - Department of Internal Medicine, Mayo Clinic

01/2002

Mayo Clinic Distinguished Clinician Award - Mayo Graduate School of Medicine, Mayo Clinic College of Medicine

01/2007

Endowed Professorship, the Maxine and Jack Zarrow Professor of Medicine - Mayo Graduate School of Medicine, Mayo Clinic College of Medicine

01/2008

Maxine and Jack Zarrow Professorship 01/2008American Gastroenterological Association Fellowship - American Gastroenterological Association

01/2010

7. Military Service8. Previous Professional Positions and Major Appointments

Assistant Professor of Medicine - Mayo Clinic College of Medicine 07/1981 - 07/1995Associate Professor of Medicine - Mayo Clinic College of Medicine 07/1995 - 07/2001


9. Professional & Community Memberships, Societies and ServicesProfessional Memberships & ServicesPhi Eta Sigma National Honor Society

Member 01/1976 - PresentAlpha Omega Alpha Honor Medical Society

Member 01/1976 - PresentAmerican College of Physicians

Member 01/1979 - PresentFellow 01/1988

American Gastroenterological AssociationMember 01/1981 - Present

Sigma Xi, The Scientific Research SocietyMember 01/1987 - Present

Crohn's and Colitis Foundation of AmericaMember 01/1990 - PresentMember 01/2001 - Present

Professional Education CommitteeMember 01/1993 - PresentChair 01/1993 -

12/1996National Scientific Advisory Committee

Member 01/1993 - 12/1999

Minnesota ChapterMember 01/1993 - PresentBoard of Directors

Member 01/1993 - 12/1999

Professional Affairs CommitteeMember 01/1996 - PresentChair 01/1996 -

12/1999American Medical Association

Member 01/1993 - PresentMinnesota Medical Association

Member 01/1993 - PresentInflammatory Bowel Diseases Forum Committee

Member 01/1994 - PresentU.S. Department of Veterans Affairs

Veteran's AdministrationGrant Reviewer 01/1997 - PresentMember 01/1997 - Present

Food and Drug AdministrationMember 01/1998 - Present


Gastrointestinal Drugs Advisory CommitteeVoting Member 01/1998 - PresentMember 01/1998 - Present

The Wellcome TrustGrant Reviewer 01/2000 - PresentMember 01/2000 - Present

American Board of Internal MedicineGastroenterology Subspecialty Board

Member 10/2012Journal Editorial ResponsibilitiesJournal of Clinical Gastroenterology

Associate Editor 01/1992 - 12/1992

Inflammatory Bowel DiseasesEditorial Board Member 01/1994 - Present

Mayo Clinic ProceedingsEditorial Board Member 01/1998 - PresentAssociate Editor 01/2001 - Present

Mayo Health O@sisInternet Web Site

Editorial Board Member 01/1998 - PresentAlimentary Pharmacology & Therapeutics

Editorial Board Member 01/1999 - PresentJournal Other ResponsibilitiesGastroenterology

Ad Hoc ReviewerMayo Clinic Proceedings

Ad Hoc ReviewerReviewer 01/1998 - Present

Journal of the American Medical AssociationAd Hoc Reviewer

American Journal of GastroenterologyAd Hoc Reviewer

Southern Medical JournalAd Hoc Reviewer

Journal of Laboratory and Clinical MedicineAd Hoc Reviewer

European Journal of GastroenterologyAd Hoc Reviewer

Diseases of the Colon and RectumAd Hoc Reviewer

Journal of Clinical GastroenterologyReviewer 01/1992 - Present

Inflammatory Bowel Diseases


Reviewer 01/1994 - PresentMayo Health O@sis

Reviewer 01/1998 - PresentInternet Web Site

Reviewer 01/1998 - PresentAlimentary Pharmacology & Therapeutics

Reviewer 01/1999 - Present

10. Educational ActivitiesA. Curriculum/Course DevelopmentB. Teaching

Intestinal Malabsorption Mayo Graduate School Rochester, Minnesota

01/1982 - 12/1989

Protein Digestion and Metabolism Mayo Medical School Rochester, Minnesota

01/1983 - 12/1992

Mayo Clinic Update in Gastroenterology Maui, Hawaii

1985

Physical Diagnosis Mayo Medical School Rochester, Minnesota

01/1985 - 12/1991

Mayo Clinic Update in Gastroenterology Buena Vista, Florida

1987

Selected Topics in Internal Medicine Mayo Clinic Scottsdale, Arizona

1988

Mayo Clinic Update in Gastroenterology St. Petersburg, Florida

1989

Enterostomal Therapy Symposium Mayo Clinic Rochester, Minnesota

1989

Internal Medicine Course Mayo Clinic Rochester, Minnesota

1989

Mayo Clinic Advances in Diagnostic Radiology Tucson, Arizona

1990

Mayo Clinic Postgraduate Course San Diego, California

1991

Inflammmatory Bowel Disease: Clinical Update Course Director, Mayo Division of Gastroenterology Continuing Education Course Mayo Clinic Rochester, Minnesota

1992

Mayo Continuing Education: Practice of Internal Medicine Mayo Clinic Rochester, Minnesota

1992

Inflammmatory Bowel Disease: Clinical Update Course Director, Combined Mayo Foundation and Crohn's and Colitis Foundation

1993


of America Continuing Education Course Mayo Clinic Rochester, Minnesota

Medical Management of IBD Division of Colorectal Surgery Rochester, Minnesota

1995

Dysplasia in IBD Division of Colorectal Surgery Rochester, Minnesota

1996

Update on the Medical Treatment of IBD Division of Colorectal Surgery Rochester, Minnesota

01/1997 - 12/1999

IBD Update Course Director Mayo Clinic Rochester, Minnesota

01/1998 - 01/2002

A New Millennium in Gastroenterology Mayo Clinic Kohala, Hawaii

1999

C. MentorshipIndividual and Position Timeframe &

DescriptionOutcomes Current Status

D. Academic Career Development

11. Institutional/Departmental Administrative Responsibilities, Committee Memberships and Other ActivitiesMayo ClinicMayo Clinic Committees

Institutional Review BoardMember 01/2002Administrative Committee

DirectorHospital Policy Committee

Member 01/1992 - 12/1993

Mayo Clinic Task Forces/Work GroupsInflammatory Bowel Disease Clinic

Director 01/1991 - Present

Member 01/1991 - Present

Department of Education AdministrationMayo Clinic College of Medicine

Mayo School of Continuous Professional DevelopmentMember 01/1992 -

PresentContinuing Medical Education



Inflammatory Bowel Disease: Clinical UpdateMember 01/1992 -

PresentProgram Director 01/1992 -

12/1992Program Director 01/1993 -

12/1993Mayo Foundation for Medical Education and Research

Director 01/2002Member 01/2002

Mayo Clinic in RochesterDepartment of Internal Medicine

Member 01/1981Internal Medicine Resident Advisory Committee

Member 01/1981 - 12/1993

Division of Gastroenterology and HepatologyMember 01/1981Recruitment Committee

Member 01/1985 - 12/1990

Executive CommitteeMember 01/1990 -

12/1993GI Division Subspecialty Directors Committee


Research CommitteeMember 01/1993 -

12/1998Mayo Clinic Rochester Committees

Mayo Clinic Transfusion CommitteeMember 01/1982 -

12/1986

12. Presentations ExtramuralNational/International

Invited

Franciscan Medical Center Rock Island, Illinois

1987

Syrian Society of Gastroenterology Meeting Damascus, Syrian Arab Republic

1988

University Hospital Aleppo, Syrian Arab Republic

1988

Indian Society of Gastroenterology National Meeting Bangalore, India

1989

Inflammatory Bowel Disease Symposium 1990


Birmingham, Alabama

Allen Memorial Hospital Waterloo, Iowa

1991

St. Olaf Hospital Austin, Minnesota

1991

Malaysin Society of Gastroenterology and Hepatology Kuala Lumpur, Malaysia

1992

Pouchitis 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis Munich, Germany

1997

Butterworth Hospital Grand Rapids, Michigan

1997

Cleveland Clinic Division of Gastroenterology Cleveland, Ohio

1998

Conventional therapy for Crohns disease Annual Meeting of the American Gastroenterological Association Orlando, Florida

1999

Pouchitis - The key of IBD etiology? International Symposium, 30 years with the ileal pouch Goteborg, Sweden

1999

Ulcerative colitis - The doctor in focus Montreuxs, Switzerland

2002

Gastrointestinal events review board Cape Town, South Africa

2002

Evolving approaches to IBD Salt Lake City, Utah

2002

Update on inflammatory bowel disease Tulsa, Oklahoma

2002

New strategies in IBD therapy Denver, Colorado

2002

New strategies in IBD therapy Birmingham, Michigan

2002

Innovations in the management of IBD New Orleans, Louisiana

2002

Digestive Disease Week India Cochin, India

2002

Innovations in the management of IBD Jackson Jackson, Mississippi

2002

IBD Meeting New Zealand Society of Gastroenterology Waihekee, New Zealand

2002

Oral

Lecturer Cedars Sinai Medical Center Symposium

1983


Los Angeles, California

Update on Gastrointestinal Disease Mercy Hospital Medical Center Des Moines, Iowa

1984

Oral Mesalamine Symposium London, United Kingdom

1987

Minnesota Academy of Family Physicians Minneapolis, Minnesota

1990

Inflammatory Bowel Diseases - Pathophysiology as Basis of Treatment Falk Symposium Regensburg, Germany

1992

Update in Internal Medicine: University of Utah Snowbird, Utah

1992

Moderator, Inflammatory Bowel Disease Therapy Oral Presentations American Gastroenterological Association Research Forum Boston, Massachusetts

1993

Moderator, Infalmmatory Bowel Disease Therapy Oral Presentations American Gastroenterological Association New Orleans, Louisiana

1994

Greater New Jersey Crohn's and Colitis Symposium Plainfield, New Jersey

1994

Inflammatory Bowel Disease Symposium. University of Louisville. Louisville, Kentucky

1994

Reaching For a Cure Medical Symposium. Crohn's and Colitis Foundation Birmingham, Alabama

1994

Reaching For a Cure Medical Symposium. Crohn's and Colitis Foundation Tampa, Florida

1994

Panelist, Case Management of Inflammatory Bowel Disease University of Chicago Chicago, Illinois

1994

Moderator, Inflammatory Bowel Disease Therapy Oral Presentations American Gastroenterology Association San Diego, California

1995

Moderator, Inflammatory Bowel Disease Therapy Oral Presentations American Gastroenterology Association San Francisco, California

1996

Update on Inflammatory Bowel Disease Genesee Hospital Rochester, New York

1996

New directions in anti-inflammatory therapy for IBD Immunological Disorders of the Intestines Symposium Buenos Aires, Argentina

1996

Immunotherapy for IBD: Conventional agents Immunological Disorders of the Intestines Symposium Buenos Aires, Argentina

1996

Immunotherapy for IBD: Experimental agents Immunological Disorders of the Intestines Symposium

1996


Buenos Aires, Argentina

Antimicrobial and nutritional therapy for IBD Immunological Disorders of the Intestines Symposium Buenos Aires, Argentina

1996

What is refractory IBD and how can we manage it with medicine? Leiden IBD-DAG Symposium Leiden, Netherlands

1996

Overview of IBD: Current Concepts, Therapies, and Research Seminar for Nurses St. Paul, Minnesota

1996

Induction of remission in Crohns disease International Meeting - Crossing Borders in IBD Barcelona, Spain

1998

Budesonide controlled ileal release capsules once or twice daily in active Crohns disease. A placebo controlled study International Organization of Inflammatory Bowel Disease Annual Meeting Noordwick, Netherlands

1998

Ulcerative Colitis The Doctor in Focus Montreux, Switzerland

2000

Regional

13. Visiting ProfessorshipsButterworth Hospital Grand Rapids, Michigan

1985

Postgraduate Course in Medicine University of Southern Calfiornia School of Medicine Hawaii

1986

A Practical Guide of Topical and Oral 5-ASA Products with Treatment in Inflammatory Bowel Disease Cedar Sinai Medical Center Los Angeles, California

1993

MeritCare Medical Center and Dakota Medical Center Fargo, North Dakota

1993

Grand Rounds Presentation Division of Gastroenterology, Eastern Virginia School of Medicine Norfolk, Virginia

1994

Grand Rounds Presentation Division of Gastroenterology, University of Alberta Alberta, Canada

1994

GI Grand Rounds Division of Gastrenterology, St. Louis University St. Louis, Missouri

1995

Medical Grand Rounds University of South Dakota Sioux Falls, South Dakota

1995

Division of Gastroenterology, University of Wisconsin 1997


Madison, Wisconsin

Division of Gastroenterology, Yale University New Haven, Connecticut

1998

Division of Gastroenterology, Case Western University Cleveland, Ohio

1999

Division of Gastroenterology, St. Louis University St. Louis, Missouri

1999

Division of Gastroenterology, University of Connecticut Farmington, Connecticut

1999

Division of Gastroenterology Case Western University Cleveland, Ohio

2000

14. Clinical Practice, Interests, and AccomplishmentsGastroenterology, with a primary interest in inflammatory bowel disease Internal Medicine

15. Research Interests

16. Educational Practice, Interests, and Accomplishments

17. Research Grants AwardedActive GrantsFederal

Consultant (MEthotrexate Response In Treatment of UC - MERIT-UC). Funded by National Institutes of Health. (U01 DK 92239)

08/15/2011 - 06/30/2017

IndustryCo-Investigator Amendment#1 - Replacement - CD INFORM: Investigating

Natalizumab through Further Observational Research and Monitoring in: Amendment#1- Replacement - CD INFORM: Investigating Natalizumab through Further Observational Research and Monitoring. Funded by Biogen Idec. (Protocol ELN100226-CD451)

11/05/2008 - 11/04/2013

Co-Investigator Millennium C13008 for ulcerative colitis / Crohn's disease. Funded by Millennium Pharmaceuticals, Inc. (C13008)

11/15/2008 - 11/14/2009

Co-Investigator SECURE / A Non-Interventional Long-term Post-Marketing Registry of Patients Treated with Certolizumab Pegol (Cimzia) for Crohns Disease. Funded by UCB Pharma, Inc. (Study C87075 Protocol RPCE08G1704)

05/01/2009 - 04/30/2019

Co-Investigator Developing a bowel damage for Crohns disease: looking beyond the mucosa. Funded by UCB Pharma, Inc.

01/01/2010 - 12/31/2010

Co-Investigator Prospective Trial Comparing REMICADE (infliximab) and Placebo in the Prevention of Recurrence in Crohns Disease Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence (PREVENT). Funded by Janssen Services, LLC. (REMICADECRD3001)

11/01/2010 - 10/31/2011

Co-Investigator A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of PF-00547659 in Subjects with Crohns disease who are Anti-TNF Inadequate Responders (OPERA). Funded by Pfizer Inc. (Protocol

08/01/2011 - 07/31/2012


#A7281006)

Completed GrantsFederal

Co-Investigator Use of symbiotics to reduce urinary oxalate excretion. Funded by National Center for Complementary and Alternative Medicine. (R21 AT 02534)

09/2005 - 09/2009

FoundationCo-Investigator Measles Vaccination and Inflammatory Bowel Disease. Funded

by American College of Gastroenterology.07/1997 - 06/1998

Co-Investigator A Cross-Sectional Study of Inflammatory Bowl Disease Patients Receiving Azathioprine or 6-Mercaptopurine to Determine the Relationship Between Thiopurine Methyltransferase Activity, 6-Thioguanine Nucleotide Concentration, and Disease Status. Funded by American College of Gastroenterology.

07/1999 - 06/2000

Co-Investigator An Epidemiological Study of Microscopic Colitis: Incidence, Prevalence, Cancer Risk and Association with Cigarette Smoking. Funded by American College of Gastroenterology.

07/2002 - 06/2003

IndustryPrincipal Investigator

Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Asacol in the Treatment of Symptomatic Crohn's Colitis and Crohn's Ileocolitis. Funded by Norwich Eaton Pharmaceuticals/Proctor & Gamble Pharmaceuticals.

01/1989 - 01/1992

Principal Investigator

Bismuth Foam Enemas For the Treatment of Chronic Pouchitis. Funded by Tillotts Pharma AG (Switzerland).

01/1993 - 01/1996


Phase II Multicenter Study of Anti-TNF Chimeric Antibody (cA2) in the Treatment of Patients with Ulcerative Colitis. Funded by Centocor, Inc.

01/1994 - 01/1995


A Randomized, Double-Blind, Placebo-Controlled Trial Of The Addition Of Bismuth Carbomer Foam Enemas To Standard Therapy For Treatment Of Ileal Pouchitis In Patients With Previous Protocoletomy And Ileal Pouch-Anal Anastomosis For Ulcerativ. Funded by Tillotts Pharma Ag. (Tillotts #1)

04/1994 - 02/1995


Phase II Multi-Center Study Of Chimeric Anti-TNF Monoclonal Antibody (cA2) In The treatment Of Patients With Ulcerative Colitis. Funded by Centocor Corporation. (Centocor #11)

06/1994 - 05/1995


Budesonide Controlled Ileal Relief Capsules Once or Twice Daily in Active Crohn's Disease. A Placebo Controlled Study. Funded by Astra Merck.

01/1995 - 01/1998


Safety, Tolerance, Pharmacokinetics And Pharmacodynamics Of Multiple doses Of Intravenous rhuIL-10(SCH 52000) In Patients With Steroid Refractory Crohn,s Disease. Funded by Schering-Plough Research Institute. (Schering #32)

02/1995 - 01/1996


Safety, Tolerance and Activity of Multiple Doses of Subcutaneous rHuLL-10 (SCH 52000) in Patients with Mildly to Moderately Active Ulcerative Colitis. Funded by Schering-Plough Research Institute. (SCHERING #35)

07/1995 - 01/1997


Safety, Tolerance and activity of Multiple Doses of Subcutaneous rHuLL-10 (SCH 52000) in patients with Mildly to Moderately Active Crohn's Disease. Funded by Schering-Plough Research

07/1995 - 01/1997


Institute. (Schering #34)


Budesonide Controlled Ileal Release Capsules. Once or twice daily in active Crohn's disease placebo controlled study. Funded by Astra USA, Inc. (Astra #10)

10/1995 - 09/1996


Treatment of Gastroduodenal Crohn's Disease with Omeprazole: A Multicenter, Blinded, Randomized Placebo Controlled Trial. Funded by Astra Merck.

01/1996 - 01/1999


Budesonide Controlled Ileal Release Capsules as Maintenance Treatment in Crohn's Disease. A Placebo-Controlled Study. Funded by Astra USA, Inc. (Astra 15)

03/1996 - 03/1999


Safety, Tolerance and Efficacy of Multiple Doses of Subcutaneous rhuIL-10 (SCH 52000) in Patients with Chronic Active Crohn's Disease in: Companion Protocol to C/195-152: Safety and Tolerance of Retreatment with Multiple Doses of Subcutaneous rHuIL-10 (SCH 52000) in Patients with Chronic Active Crohn's Disease. Funded by Schering-Plough Research Institute.

03/1996 - 02/2003


Companion Protocol to C/195-152: Safety and Tolerance of Retreatment with Multiple Doses of Subcutaneous rHuIL-10 (SCH 52000) in Patients with Chronic Active Crohn's Disease. Funded by Schering-Plough Research Institute. (Schering 41)

03/1996 - 09/2003


Proposal for the Development of Guidelines for Clinical Practice in Inflammatory Bowel Disease. Funded by Solvay. (Solvay #1)

04/1996 - 03/2003


Treatment of Gastroduodenal Crohn's Disease With Omeprazole: A Multicenter Controlled Trial. Funded by Astra Merck. (Astra #9)

05/1996 - 07/2000


Safety, Tolerance, and Efficacy of Treatment with Subcutaneous rHuIL-10 (SCH 52000) in subjects with Steroid-Dependent Crohn's Disease. Funded by Schering-Plough Research Institute. (Schering 62)

06/1998 - 05/1999


Open-Label, Two Stage Pilot Study to Determine the Study, Tolerability, Steady-State Pharmacokinetics and Potential Efficacy of Subcutaneous APL 2059 for Patients With Mild to Moderate Active Ulcerati. Funded by Axys Pharmaceuticals.

01/1999 - 01/2002


A Placebo Controlled Trial of Alendronate for the Prevention of Osteoporosis in Patients with Inflammatory Bowel Disease. Funded by Merck & Co., Inc.

01/1999 - 01/2002


Assessment of Ulcerative Colitis Disease Activity and Treatment Response-Time Using Scintigraphy. Funded by Solvay Pharmaceuticals.

01/2000 - 01/2002


Open-Label, Two-Stage Pilot Study to Determine the Safety, Tolerability, Steady-State Pharmacokinetics and Potential Efficacy of Subcutaneous APC 2059 for Patients with Mild to Moderate Active Ulcerative Colitis or Proctosigmoiditis. Funded by Axys Pharaceuticals, Inc. (AXYS 1)

01/2000 - 12/2003


Expression of hGRB in Ulcerative Colitis Patients Who are Refractory to Corticostreoids Compared to Patients who are Steroid Responsive? Funded by Astra Merck. (ASTRAZENECA #6)

02/2001 - 01/2003

Principal Safety and Efficacy of Two Dose Regimens of CB-1011 01/2002 - 12/2002


Investigator (Medrozyprogesterone Acetate, MPA) in Patients with Active Crohn's Disease: A Randomized, Double-blind, Placebo-Controlled, Multicenter Trial. Funded by InKine Pharmaceutical Company. (INKINE #1)


Late Onset IBD. Funded by Procter and Gamble. (PROCTER #23; 1A5347)

10/2004 - 09/2005

Program Director / Principal Investigator

Influence on Medical Therapy on Proximal Progression of Left-sided Ulcerative Colitis. Funded by Procter and Gamble. (Program ID#: 5956940)

11/2006 - 10/2009

Program Director / Principal Investigator

Efficacy of Oral Mesalamine in the Treatment of Crohn's Colities - A Retrospective Study. Funded by Procter and Gamble.

09/2007 - 08/2009

Co-Investigator Placebo-Controlled Trial of 5-aminosalicylic acid Enemas in Ulcerative Proctosigmoiditis. Funded by Reid Rowell Pharmaceuticals.

01/1983 - 01/1984

Co-Investigator Oral 5-aminosalicylic acid in the Treatment of Ulcerative Colitis, Collagenous Colitis and Crohn's Disease. Funded by Tillotts Labs (England) and Norwich Eaton Pharmaceuticals.

01/1984 - 01/1992

Co-Investigator Cyclosporine Enemas for Ulcerative Proctosigmoiditis. Oral Cyclosporine for Treatment of Crohn's Disease. Funded by Sandoz Pharmaceuticals.

01/1991 - 01/1992

Co-Investigator Randomized, Placebo-Controlled Trial of the Addition of the Trans-dermal Nicotine Patch to Current Therapy for Mildly to ModerateActive Ulcerative Colitis in Lifetime Non-Smokers and Ex-Smokers. Funded by ELAN Pharmaceuticals.

01/1992 - 01/1994

Co-Investigator An International Study to Assess Health Related Quality of Life and Its Predictors in Inflammatory Bowel Disease. Funded by Astra Pharmaceuticals. (Astra #8)

12/1995 - 11/1996

Co-Investigator Evaluation of ANCA, ASCA, and APA as Serologic Disease Markers in a Population Based Cohort of Patients with Ulcerative Colitis and Crohn's Disease. Funded by Prometheus Laboratories, Inc. (Prometheus 1)

10/1997 - 07/2000

Co-Investigator A Pharmacodynamic and Pharmacokinetic Study to Determine the Clinical Significance of Drug Interactions Between Azathioprine and Sulfasalazine or Pentasa in Patients with Inflammatory Bowl Disease. Funded by Procter and Gamble. (Proctor 10)

11/1998 - 10/2000

Co-Investigator Costs of Illness in Crohn's Disease: Comparison Between Clinical Phenotypes in: Costs of Illness om Crohn's Disease: Comparison Between Clinical Phenotypes. Funded by Schering-Plough Research Institute. (INTEGRATED 7)

04/1999 - 03/2003

Co-Investigator Determining the Clinical Outcome and Side Effects Associated with the Treatment of Patients with Crohn's Disease with the Anti-TNF Antibody, Infliximab. Funded by Centocor Corporation. (CENTOCOR 13)

06/1999 - 05/2003

Co-Investigator Registry of Crohn's Patients Some of Whom Have Been Treated with Remicade. Funded by Centocor Corporation. (TREAT-PHYSICIAN PARTICIPATION AGREEMENT)

11/1999 - 10/2009


Co-Investigator A Randomized, Placebo-Controlled Trial of Alosetron in Microscopic Colitis. Funded by Glaxo Wellcome, Inc. (GLAXO #87)

06/2000 - 05/2002

Co-Investigator Therapeutic Effect of Lactic Acid Bacteria in Enteric Hyperoxaluria. Funded by VSL Pharmaceuticals. (VSL#2 1A4393)

01/2002 - 12/2006

Co-Investigator Effect of 5-Aminosalicylates on Progression of Indefinite or Low-Grade Dysplasia to Advanced Neoplasia in Ulcerative Colitis. Funded by Procter and Gamble. (PROCTER #22; 1A5232)

07/2004 - 07/2006

Co-Investigator A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis. Funded by Centocor Research & Development, Inc. (C0524T17)

06/2007 - 05/2008

Co-Investigator A Phase 2/3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis in: A Phase 3 Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects with Moderately to Severely Active Ulcerative Colitis. Funded by Centocor Research & Development, Inc. (C0524T18)

06/2007 - 01/2012

Co-Investigator A phase IV, multi-center, open-label study to assess clinical recurrence related to compliance with treatment with MMX mesalamine 2.4g/day given once daily for the maintenance of quiescent ulcerative colitis (UC). Funded by Shire Development, Inc. (SPD476-404)

06/2007 - 06/2008

Co-Investigator A Randomized, Double-Blind, Placebo-Controlled, Parallel Center Study to Investigator the Safety an Efficacy of CP-690,550 in Subjects with Moderate to Severe Crohn's Disease in: Pfizer CP-690,550. Funded by Pfizer Inc. (Protocol #3921043)

01/2008 - 01/2009

Co-Program Director / Principal Investigator

Abbott ABT-874 Protocol No. M10-222 in: Abbott ABT-874 Protocol Number M10-222. Funded by Abbott Laboratories. (M10-222)

01/2008 - 01/2010


Amendment#3-Replacement-Abbott ABT-874 Protocol Number M10-222 in: Abbott ABT-874 Protocol Number M10-222-A Phase 2B, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study Comparing the Efficacy,. Funded by Abbott Laboratories. (M10-222)

01/2008 - 01/2010


Amendment#2-Replacement-Abbott ABT-874 Protocol Number M10-222-A Phase 2B, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study Comparing the Efficacy, in: Amendment #2-Replacement-Abbott ABT-874 Protocol Number M10-222-A Phase 2B, Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study Comparing the Efficacy,. Funded by Abbott Laboratories. (M10-222)

01/2008 - 01/2010

Co-Program Novartis AIN457 Protocol Number CAIN457A2202. Funded by 01/2008 - 01/2009


Director / Principal Investigator

Novartis.

Co-Investigator Lactoferrin as a Predictor of Early Relapse in Infammatory Bowel Disease in: Lactoferrin TechLab Budget. Funded by Techlab.

06/2008 - 06/2009

Co-Investigator Adalimumab Open-Label M10-223. Funded by Abbott Laboratories.

08/2008 - 07/2011

Co-Investigator Centocor CNTO 1275 Ustekinumab. Funded by Centocor Research & Development, Inc. (Protocol C0743T26)

08/2008 - 08/2009

Co-Investigator "C13006-A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis". Funded by Millennium Pharmaceuticals, Inc. (C13006)

09/2008 - 09/2009

Co-Investigator Millennium C13007 for Crohn's disease. Funded by Millennium Pharmaceuticals, Inc. (C13007)

09/2008 - 09/2009

Co-Investigator A Phase 3b/4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status During a 12-Month, Long-term Maintenance Phase With 2.4g/day MMX Mesalamine/mesalazine Once Daily in Adult Subjects With Ulcerative Colitis. Funded by Shire Development, Inc. (Protocol No. SPD476-409)

09/2010 - 08/2011

Co-Investigator A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohns Disease in: CENTERPHASE: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects with Moderate to Severe Crohns Disease. Funded by Amgen. (Protocol No. 20090072 / Contract 136397)

12/2010 - 12/2011

Co-Investigator A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to-Severely Active Crohns Disease in: A Randomised, Double-blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects with Moderately-to-Severely Active Crohns Disease. Funded by GlaxoSmithKline. (Protocol CCX114151)

01/2011 - 01/2012

Co-Investigator A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohns Disease in: C13011 A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction of Clinical Response and Remission by Vedolizumab in Patients With Moderate to Severe Crohns Disease. Funded by Millennium Pharmaceuticals, Inc. (Protocol C13011 / Appendix Agreement # 222081)

02/2011 - 01/2012

Consultant Epidemiology, Severity, and Clinical Course of Crohn's Disease and Ulcerative Colitis in Olmsted County. Funded by Schering-Plough Research Institute. (Schering 36)

10/1995 - 12/1998

Mayo Clinic



Pilot Study using Short Chain Fatty Acid Enemas in the Treatment of Ileoanal Pouchitis. Funded by Mayo Foundation Research Committee.

01/1989 - 01/1990


Prevention of Osteoporosis in IBD with Alendronate. Funded by CR Programs.

08/2000 - 07/2002

Co-Investigator A Dose Ranging Pharmacokinetic study of Nicotine and Nicotine-Carbomer Formulations in Healthy Human Volunteers Following Single dose IV and Delayed-Release Oral Administration. Funded by Mayo Rochester.

04/1996 - 03/1997

Co-Investigator Early Measles Virus Infection and Inflammatory Bowel Disease. Funded by Mayo Protocol.

03/1997 - 02/1999

Co-Investigator A Phase I Study to Determine the Optimum Dose and Dosing Schedule of Intravenous Azathioprine Loading to Decrease the Time to Response in Patients with Active, Steroid-Refractory Ulcerative Colitis. Funded by CR Programs.

10/1997 - 09/2000

Co-Investigator Colonic Motility in Ulcerative Colitis. Funded by CR Programs. 01/1998 - 12/1998

Co-Investigator A Pharmacodynamic and Pharmacokinetic Study to Determine the Clinical Significance of Drug Interactions Between Azathioprine and Sulfasalazine or Pentasa in Patients with Inflammatory Bowl Disease. Funded by Mayo CR20 Funding.

12/1998 - 11/1999

Co-Investigator Cross-Sect'l Study, Inflammatory Bowel Disease Pts Recv'g Azathioprine/6-Mercaptopurine & Relationship b/t Thiopurine Methyltransferase Activity, 6-Thioguanine Nucleotide Concentration, Disease Status inc Leukopenia. Funded by CR Programs.

03/1999 - 12/2000

Co-Investigator Imaging Small Bowel Crohn's Disease: A Feasibility Study Comparing Optimized CT with Small Bowel Follow Through Examinations. Funded by CR Programs.

10/1999 - 09/2000

18. Patents

Title Patent Number Date filed Date issued

William J. Tremaine, MD Page of

RE-AIMS 04/08/2015

Local DiskTremaineCV.htm

william tremaine cv

Documents